CD19 and neoplasm: In contrast, all CAR19-NK-92-treated groups displayed delayed tumor progression compared to the NK-92 control group, highlighting the critical role of CAR constructs in mediating CD19-specific tumor targeting and cytotoxicity (Figure 5B).